News
Innovative Treatment for Ameloblastoma Provides Patients With New Hope
Ameloblastoma is a disorder of the jaw involving abnormal tissue growth. It is a very rare (about 1% of all jaw tumors) and slow-growing tumor that develops in the space behind our molar or back teeth. Ameloblastoma can occur over a broad age range, most commonly affecting patients between the ages of 20 and 40. […]
Read More
New Sheba Study Finds: Immunotherapy Effective for Basal Cell Carcinoma Skin Cancer
Basal cell carcinoma (BCC) is a type of cancer that most often develops on areas of skin exposed to the sun, such as the face, and is the most common form of skin cancer. Traditionally, BCC is treated with surgery to remove the malignant tissue. When the type of the tumor does not allow for […]
Read More
For the First Time in Israel: A New Non-invasive Mitral Valve Replacement Procedure
Doctors at Sheba Medical Center performed a transcatheter mitral valve replacement on a 74-year-old patient using the cutting-edge LAMPOON technique.
Read More
COVID-19 Booster Shot Increases Protection Against Delta Variant Infection by 85%, Study Indicates
Those who received a third dose of the COVID-19 vaccine are 85.6% less likely to contract the disease compared to people who were only vaccinated twice.
Read More
Sheba leads Forbes’ Best Doctors in Israel List for 2021
Forbes’ Best Doctors in Israel List includes 1,350 clinicians, 216 of which are Sheba’s own.
Read More
Sheba Partners with Two of the Largest Bahraini Hospitals
The agreement involves sharing knowledge, conducting joint research, training staff, and more.
Read More
The latest step in the collaboration between Sheba and UAE health authorities
Sheba’s Prof. Dudkiewicz visited UAE hospitals to share his unique know-how.
Read More
A Sheba Study Examines How Mitochondria Affect the Immune System and Microbiome.
Researchers were awarded a 2.1 million USD grant that will fund the next step of the study.
Read More
Sheba’s study indicates the Importance of a Third COVID-19 Vaccine Dose
Research suggests a significant decrease in immune response a few months after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine
Read More